Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131937 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
A Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00131937: Completed Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by National Cancer Institute (NCI).
NCT00131937 is a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131937, a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Primary Outcome
Response was assessed using the criteria from International Workshop to Standardize Criteria for NHL (Cheson, 1999). OR=complete response(CR)+complete response/uncertain(CRu)+partial response(PR) CR: 1)Disappearance of clinical/radiographic evidence of disease (dz) and all dz-related B-symptoms; normalization of biochemical abnormalities attributed to NHL; 2)Lymph nodes and nodal masses regress to normal size; 3)Spleen, if enlarged before therapy, has decreased in size and is not palpable; 4)Com
Conditions Studied
Interventions
- DRUG sorafenib tosylate
Study Locations (1)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT00131937 record still lists
NCT00131937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (87% lower).
The record links to 8 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which sorafenib tosylate is the first listed.
NCT00131937 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00131937 about?
NCT00131937 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma". This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00131937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-10. Estimated completion is 2012-08.
What conditions does trial NCT00131937 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma.
What interventions are being tested in trial NCT00131937?
The interventions under investigation include: sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00131937?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00131937 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00131937's enrollment target sits among peer trials
14 30th of 34 higher than 5 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia